ResMed CFO acquires stock units, director departs

Brett Sandercock, ResMed Inc.'s chief financial officer, reported the acquisition of 2,710 common stock units on November 20, 2025. These units, granted on November 16, 2022, were earned after the compensation and leadership development committee certified performance metrics. Post-transaction, Sandercock beneficially owns 88,495 shares.

Concurrently, Richard Sulpizio ceased to serve as a director of ResMed Inc. on November 19, 2025, following the conclusion of the 2025 annual meeting of stockholders. After his departure, Sulpizio beneficially owns 17,796 common stock units.